Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review

Hepatic dysfunction, in the absence of liver metastases, occurs in 10–15% of renal cell carcinoma (RCC) patients, while immune hepatitis due to anti-CTLA4 and anti-PD1 administration affects about 3–9% and 0.7–1.8% of treated patients, respectively. Liver toxicity following combination therapy (anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Denaro, Nerina, Garrone, Ornella, Occelli, Marcella, Fea, Elena, Granetto, Cristina, Merlano, Marco Carlo, Numico, Gianmauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276930/
https://www.ncbi.nlm.nih.gov/pubmed/34268267
http://dx.doi.org/10.12890/2021_002639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276930/
https://www.ncbi.nlm.nih.gov/pubmed/34268267
http://dx.doi.org/10.12890/2021_002639

Ejemplares similares